## A cross sectional serologic and epidemiological study of dengue virus infection in north central area of Trinidad and Tobago.

6 7 8

1

2

3

4

5

### ABSTRACT

Aims: This study was carried out to determine the observed serological and significant epidemiological risk factors for dengue fever infection in a cross-section of the population in Trinidad and Tobago.

Study design: This was an observational cross sectional study.

Place and Duration of Study: The study was carried out in the department of Paraclinical Sciences of the University of the West Indies, St. Augustine Campus, Trinidad and Tobago, over a period of 10 months. October 2016 to July 2017.

**Materials and Methods:** Over 450 individuals from a cross section of the population residing in the northern part of Trinidad Island were surveyed. These included individuals suspected of having dengue fever that presented to the health care facilities with complaints of fever along with some other symptoms suggestive of dengue viral illness. There was no age, gender or ethnic bias. Standardized questionnaire was used to obtain epidemiological data. Blood samples taken from consented participants were analyzed using rapid immune chromatographic tests (ICTs) - Panbio, SD Bioline and Enzyme Linked Immunosorbent Assays (ELISA). The samples were also tested for baseline blood parameters such as platelets and haemoglobulin. The epidemiological data was analyzed using SPSS version 21.

Results: Analysis of 380 individuals who fulfilled study criteria revealed that there were no demographic characteristics (age, gender, locality, etc.) that showed statistical significance with having a dengue infection. Retro-orbital pain, headaches and respiratory symptoms (e.g., cough, cold) showed differences that were significant with those having a dengue infection. No statistical significance was found in any comorbidity (diabetes, hypertension and asthma) factors considered and patients with dengue infections. Evaluation of platelet counts showed that only 5.4% samples had abnormal range, while 80% those that tested positive were not significant either. Monitoring of platelet levels is still very important, but it showed that it is not an indicator of worsening dengue because 95.3% of the positive cases were within normal levels.

**Conclusions:** Except for nonspecific symptoms observed among patients suspected of dengue fever, there were no other significant factors that were exclusive in identifying dengue infection among the subjects studied. Platelet monitoring may not be the only parameter to use in determining deteriorating dengue patients. Vector eradication activities should be intensified with other efforts such as education program.

9

Keywords: Dengue fever, ELISA, Epidemiology, Serology, Panbio, Trinidad and Tobago.

### **1. INTRODUCTION**

Dengue is a global public health problem and in the last decade has increased substantially due to human travel and changing suitability for the mosquito vector<sup>1, 2, 3</sup>. Dengue is endemic in more than 100 countries with an estimated 50 – 100 million infections annually<sup>4, 5.</sup> Dengue fever is an acute 14 15 16 manifestation of an arthropod borne viral infection belonging to the Flaviviridae family. The dengue 17 18 virus is transmitted by female mosquito Aedes aegypti. Four serotypes of the virus are known to exist 19 DEN-1-4°, and a recently documented fifth serotype appears to have been emerged'. Classic dengue 20 fever is usually self-limiting, especially in children. Dengue infection characterized by sudden onset of 21 headache, retro-orbital pain, high fever, joint pain and rash. More serious manifestations dengue virus infection includes the dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS).<sup>2</sup> 22 Dengue haemorrhagic fever is associated with re-infection, characterized by the defects in 23 24 homeostasis and plasma leakage into interstitial spaces associated with increased levels of 25 vasoactive cytokines<sup>8</sup>. This leads to life threatening shock (DSS) in some cases. 26

10 11 12

27 The severe syndromes occur in patients with passively acquired or pre-existing, non-neutralizing, 28 heterologous antibody caused by a previous infection with a different serotype of the virus<sup>9</sup>. The 29 antibodies from the previous infection bind to the new infecting serotype and facilitate viral entry via 30 Fc-receptor binding cells, so the number of antigen-presenting cells is increased at secondary 31 infection.<sup>8</sup> In 2016, there was a recorded 1,801 probable cases alone in Trinidad and Tobago out of the total 9,993 probable cases in the non-Latin (English, French and Dutch) Caribbean<sup>10</sup>. This is a 32 33 significant decrease in the number of reported probable cases when compared to 2014; with 5,157 34 probable dengue cases. As was noted in a prospective sero-epidemiological study from Trinidad and 35 Tobago, many dengue infections do not produce severe symptoms and the number of reported cases underestimates the actual prevalence of dengue in the population<sup>11, 12</sup> 36

The aim of this study was to serologically confirm the frequency of dengue virus infection and determine epidemiological risk factors associated with dengue infections among patients suspected of having dengue fever and attending health care facilities in the north central region of Trinidad and Tobago.

41 42 **2. M** 

#### 2. MATERIAL AND METHODS


#### 43 44

#### 2.1 Study design, sites and population

45 This was an observational cross sectional study conducted during the period of October 2016 - July 46 2017, among patients with suspected dengue infection. The study was carried out at two health care 47 facilities of the North Central Regional Health Authority (NCRHA) in Trinidad of the twin Island, 48 Trinidad and Tobago with catchment areas as indicated in the figure below (Figure 1). This area has a 49 high population density in the country and most dengue cases in the past were localized to this 50 region.<sup>13</sup> This region was chosen as the area of study so as to reassess the current burden of dengue virus infection. This study was carried out among patients who presented to these health care facilities 51 52 with suspected dengue infection. Suspected dengue infection is characterized by fever along with the 53 following symptoms - anorexia, rash, aches and pains, vomiting and nausea, abdominal pains and 54 warning signs include positive tourniquet test, leukopenia, thrombocytopenia (platelet count <150 × 55 10<sup>9</sup>/L), abdominal tenderness, clinical evidence of plasma leakage and/or increase in haematocrit<sup>14</sup>. 56 The study enlisted voluntary participants who gave written consent and were systematically randomly 57 selected. Standardized data collection form was used to obtain epidemiological information from all enrolled participants who were seen and physically examined by a medical personnel in the study. 58

59

Figure 1. Geographical map of Trinidad and Tobago showing the locality of individuals
 surveyed for dengue virus fever in Trinidad and Tobago.



#### 64 **2.2 Inclusion criteria**

65

All patients of all age groups, gender, ethnic groups, social and educational level who presented to these health facilities with suspected dengue infection symptoms as enumerated above and gave written consent or assent were included in the study. Any patient who did not meet the previously mentioned requirements for suspected dengue infection or did not give consent was excluded from the study.

72 2.3 Collection of Specimen

A standardized questionnaire was used to obtain patient biodata or information and clinical history.
This was administered by one of the trained investigators to avoid bias and misinterpretation or
misrepresentation of the responses from the participants.

About 10ml of blood (5ml each in red and purple top tubes) was obtained through venipuncture and transported to the Department of Paraclinical Sciences, The University of West Indies, St. Augustine Campus; and Pathology Laboratory at the Eric Williams Medical Sciences Complex for further analysis. The blood samples were allowed to clot at room temperature, centrifuged and separated as soon as possible the same day for the rapid kits (Panbio and SD Bioline). They were then stored at 2-8°C for a maximum of two days or stored frozen at -30°C until complete testing using the ELISA kits that were performed in batches.

#### 85 2.4 Laboratory Analysis - Complete Blood Count

86 87

88

89

84

All samples were subjected to a routine complete blood count as part of the routine services offered to the patients by the health care facilities including platelet counts for each patient.

#### 90 2.5 Rapid Immuno-chromatographic tests (ICTs)

91

92 The samples collected in the red top tubes were subjected to serological analysis using enzyme 93 linked immunosorbent assay - ELISA, (Dengue Virus IgM/IgG capture DxSelect ELISA, Focus 94 Diagnostics, Cypress, PA, USA) for detection of human serum IgM and IgG antibodies in dengue 95 virus (DV) infections. Rapid immune-chromatographic tests (ICT) kits were used for detection of IgM 96 and IgG antibodies, and non-structural protein 1 (NS1) antigen; of sera collected and the results were 97 recorded. The relative sensitivity and specificity for the Panbio rapid ICT is 96.3% (90.8 -99.0 %) and 98 95.0% (87.7 – 98.6%), respectively. The sensitivity and specificity of the SD Bioline rapid ICT is 92.8% and 98.4%, respectively. The kits were used within one to three months of procuring them from 99 100 the distributors and manufacturers, while their life span (expiration dates) were still within two to three 101 years.

102

#### 103 **2.6 Quality Controls**

104 Controls for both the IgM/IgG ELISA kits were provided as follows: detectable controls (human sera), 105 non-detectable controls (human sera) and cut-off calibrators (human sera). Samples that were 106 collected from asymptomatic and healthy individuals during the time of the study were used as 107 controls for both of the rapid ICT tests. Controls were run every time when procedures were carried 108 out.

109

#### 110 2.7 Statistical Analysis

111 Microsoft Excel was used for data entry and data analysis was performed using Statistical Package 112 for the Social Sciences (SPSS) 23.0 software. Chi-square test and Fisher's exact test were used to 113 compare categorical variables. The Chi-square was chosen for determination of association between 114 a tested variable and a positive dengue result. If a relationship existed between any of the variables, 115 the Chi-square value (p value) would reflect the strength of the association. The Fisher's exact test is 116 used in place of the Chi-square to measure the same association for smaller sample sizes. In cases 117 where the frequency counts are fewer than five in a two by two table, the test statistics (p) used is the 118 Fisher's exact value. A probability value (p) of < 0.05 was considered statistically significant.

- 119 120 **3. RESULTS**
- 121

More than 450 individuals were recruited for this study but only 380 of these gave consent, completed the questionnaire, got evaluated, had venipuncture and were included in the final analysis. Patients included were noted to have come from different ethnic groups of people living in this part of the
country. Among the study participants, 38.7% were of mixed ethnicity followed by patients of African
descents, 36.6%. The East Indian and Spanish descents were 22.6% and 1.1% respectively. Most of
the study participants were females (61.3%) and the median age of all analyzed individuals in the
study was 26 years (range, 3 years to 87 years) but the prevalent age group surveyed was between
21 – 30 years (Figure 2). The median time between onset of illness and collection of specimens was 3
days (range, 1 to 50 days).

131

153

164

132 As shown in Table 1, the laboratory tests of the blood samples using the ELISA reference for dengue 133 IgM and IgG, initially classified the analysis as 92.5% positive for dengue and 7.5% non-dengue. Of 134 those that tested positive for dengue, females were in the majority (60.5%) and 32.6% of all positive 135 cases were between the ages of 21-30 years old. Based on the clinical history, presentation of fever, 136 body aches and headache, the blood samples and the subjects were further defined or classified as 137 acute cases or phase (74.2 %), convalescent cases or phase (18.3 %); and based on immune status, 138 as primary 5.4 % or secondary, 87.1 %. An acute sample was recorded as one with ≤7 days post 139 onset of symptoms while those ≥7 days post onset of symptoms were recorded as convalescent. 140

Demographics were the first parameters used to determine what would qualify as risk factors in acquiring a dengue infection. Being of a particular ethnic group had no bearing or significance on whether the patient tested dengue positive. The majority of the positives (38.4%) were found to be of 'mixed' descent, followed by African descent (37.2%). There was also no association between living in a particular area and contracting dengue, although most recruits were from the Arima area (Figure 1 above), and there was a high percentage (47.3%) that tested positive there.

The statistical analysis in this study revealed that retro-orbital pain, respiratory symptoms (cold, cough, runny/stuffy nose) and headache had significant association with samples that tested positive for dengue (p < 0.05), Table 1. More than half (53.3 %) of patients surveyed that tested positive for dengue reported experiencing retro-orbital pain; 88.4 % of dengue- positive patients experienced headaches while 80.2 % experienced respiratory symptoms (Table 1).

154 Platelet levels of the patients were analyzed and categorized as abnormal ( $\leq 150 \times 10^{9}/L$ ) and normal 155  $(\geq 150 \times 10^9/L - 450 \times 10^9/L)$ . As shown on Table 2, the largest numbers of dengue positives were 156 found in the age group 21-30, 27.9% in the normal platelet range and 4.7% in the abnormal platelet 157 range, however, this difference was not statistically significant (p = 0.172). The age group 11-20 158 showed the second highest number of dengue positives with 18.6%. The mean age of those that 159 tested positive was 29 years old, while the mean platelet counts were 130,000 and 293,000 within the 160 abnormal and normal range, respectively. Except for the age groups 21 - 30 that recorded abnormal 161 platelet counts, all the other age groups had no abnormal platelet counts (Table 2). 162

#### 163 **DISCUSSION**

165 The objective of this study was to use serological analysis to determine the frequency of dengue virus 166 infection and make association between epidemiological risk factors that may exist among the 167 patients suspected of the infection in a cross section of individuals in Trinidad and Tobago. Results 168 from studies such as this can assist physicians in making definitive diagnosis of dengue in our locality 169 since many cases go unnoticed or recorded as acute viral illness (AVIs). While accurate laboratory 170 diagnosis can be very helpful in confirming the disease, it will also provide key data on the 171 epidemiology and health burden of dengue, which is very useful for accurate public health 172 surveillance<sup>19</sup>. Detection of seropositive cases of dengue in this region of study still suggest that 173 vector control operations that have previously been carried out in this region failed to achieve the 174 desired target of reducing mosquito densities in the eight counties to below the disease transmission threshold as previously reported by Chadee et al.<sup>13</sup> These authors had reported two decades ago that 175 176 the Trinidad vector control program relied on the chemical approach with the application of insecticides in artificial containers;<sup>13</sup> and this has continued to date. Perhaps more intensive and 177 178 aggressive efforts may turn to health education.

- 179
- 180

Females were noted to be the majority (60.5%) of the dengue cases in our study which is different from what has been reported in other countries.<sup>16</sup> Adults were more affected in our analysis with ages 21-30 having 32.6% of all positive cases. This again was not in agreement with Anker and Arima that reported more of their positive cases occurring more in those over 15 years in the countries they studied.<sup>16</sup> Anker and Arima attributed the dominance of the males and the age group to cultural and economic reasons. Female were more perhaps because more took part in the study despite the fact that participants were systematically selected randomly. Economic differences could not have influenced our results as reported by others<sup>16</sup> since medical care is free in our country and so all are afforded the opportunity to seek medical care.

190


191 In this study, similar number of individuals reported their ethnicity to be either of African descent or 192 mixed race; and many of these tested positive for dengue virus infections. This was not in agreement 193 with what was reported by Rojas et al in Colombia that Afro-Colombians population had a significantly 194 lower risk of getting dengue and its complications, compared with the non-Afro-Colombians 195 population.<sup>17</sup> Trinidad and Tobago is a cosmopolitan society with several ethnic groups, although the 196 African and Indian descents dominates in number; but dengue virus infection could not be selective 197 because all the different groups live together. Also majority of the participants surveyed gave their 198 location to be Arima area which was also noted to be a significant factor in this study. The high 199 number of positive results in each of these categories appears to only reflect the majority within the 200 sampled population.

201

202 Symptoms were statistically analyzed to determine their associations with a dengue virus infection 203 although dengue infections may initially be asymptomatic in 50 – 90% of individuals<sup>18</sup>. The significant 204 ones include retro-orbital pain (eye pain), headaches and respiratory symptoms which are similar to a previous report<sup>19</sup>. Eye pain is particularly common in dengue infection along with headaches but the 205 206 degree to which they are experienced are not quantifiable and so they remain non-specific. Most 207 patients who tested positive for dengue antibodies also complained of body pains; but this was not 208 found to be significant. Reporting of having a previous infection of either dengue, chikungunya or zika, 209 also did not show any differences for those who tested positive. Among the several patients that had 210 already suffered from a dengue infection, none of them showed signs or symptoms that were more 211 severe than those who said they never were infected with dengue. As dengue is one of the most 212 under reported tropical diseases, it is very possible that patients who claimed to have never had 213 dengue may be unaware of the past diagnoses seeing that symptoms are non-specific and home 214 remedies are administered by patients themselves until symptoms subside. This way, there is and can 215 be no accurate monitoring of the actual disease or possible burden of infection.

- 216
- 217

# Figure 2. Age and gender distribution of participants surveyed for dengue virus infections in Trinidad and Tobago. 220



Characteristics		Negative <mark>(%)</mark>	Positive <mark>(%)</mark>	<i>p</i> value	
Demographics	Male	8 (28.6)	139 (39.5)	0.702	
	Female	20 (71.4)	213 (60.5)	0.702	
	African descent	12 (42.9)	131 (37.2)	1.000	
	East Indian descent	4 (14.3)	82 (23.3)	1.000	
	Mixed	12 (42.9)	135 (38.4)	1.000	
	Spanish	0	4 (1.2)	1.000	
Symptoms	Rash	4 (14.3)	41 (11.6)	1.000	
	Headache	16 (57.1)	311 (88.4)	0.054	
	Retro-orbital pain	0	188 (53.5)	<mark>0.012*</mark>	
	Body pain	20 (71.4)	274 (77.9)	0.654	
	Joint pain	4 (14.3)	176 (50)	0.115	
	Diarrhoea	8 (28.6)	119 (33.7)	1.000	
	Cough, cold,				
	runny nose	8 (28.6)	282 (80.2)	<mark>0.007*</mark>	
	Gum/Nose bleeds	0	33 (9.3) 1.000		
Previous infecti	ons None	28 (100)	254 (72.1)	0.184	
	Dengue	0	65 (18.6)	0.600	
	Chikungunya	0	29 (8.1) 1.000		
	Zika	0	4 (1.2)	1.000	
	Hypertension	0	17 (4.7)	1.000	
	Diabetes	0	8 (2.3)	1.000	
	Diabetes + HTN	0	4 (1.2)	1.000	
	Asthma	0	37 (10.5)	1.000	
	Other – Arthritis,				
	PCOS, etc.	4 (14.3)	29 (8.1)	0.479	
	None	24 (85.7)	254 (72.1)	0.670	
Mosquito Cond	itions				
Many mosquitoes in the area		24 (85.7)	237 (67.4)	0.428	
Nets/Screens at home		0	61 (17.4)	0.593	
Blocked drains around house		0	70 (19.8)	0.342	
	en often	20 (71.4)	193 (54.7)	0.459	
No mosquito problems		4 (14.3)	111 (31.4)	0.670	

## 224Table 1. Characteristic features of individuals surveyed for dengue virus infection in the north225central regional health authority, Trinidad and Tobago, 2016 – 2017.

\*p < 0.05 is considered statistically significant. P-values were determined using Chi – square tests. Data are presented as n (%) or median (interquartile range); HTN – hypertension, PCOS – polycystic ovary syndrome

266 Co-morbidities such as hypertension, diabetes mellitus and asthma are among the noncommunicable illnesses that are most prevalent in Trinidad and Tobago<sup>20</sup>. If left unmanaged they can 267 268 lead to high morbidity and mortality rates. Whether or not either of these had any effects on the 269 prevalence of dengue infection was also investigated. Most of those that were found positive for 270 dengue infection showed no significant associations with having any medical conditions (asthma, diabetes, hypertension), being on any particular medications or having received any vaccines in the 271 272 last two months prior to being enrolled. However, a study in Asia, attempted to show the association of diabetes mellitus with DHF. The study found that female, Chinese, age group 30-49 years with pre-273 existing diabetes mellitus or diabetes with hypertension were risk factors of developing DHF during an 274 epidemic while dengue serotype 2 was predominant<sup>21</sup>. As stated above, neither of these 275 276 characteristics were found to show any significant differences in our current study despite age group 277 (21-30 years), gender (more females than males) or ethnicity (more of mixed ethnic group descents) 278 gave more numbers; and also the fact that 25.5% of the sampled population in this study suffered 279 from comorbidities.

280 281

262

263

264

265

201

283 Table 2. Age distribution of participants for dengue who were ELISA positive categorized by 284 platelet counts.

Age Groups	Negative ELISA		Positive ELISA	
	Abnormal <mark>(%)</mark>	Normal <mark>(%)</mark>	Abnormal <mark>(%)</mark>	Normal <mark>(%)</mark>
1 – 10	0 (0)	16(4.3)	0(0)	45(11.8)
11 – 20	0(0)	8(2.1)	0(.0)	65(17.2)
21 – 30	4(1.0)	0(.0)	16(4.3)	98(25.8)
31 – 40	0(.0)	0(.0)	0(.Ò)	38(9.7)
41 - 50	0(.0)	0(.0)	0(.0)	33(8.6)
51 – 60	0(.0)	0(.0)	0(.0)	41(10.8)
61 – 70	0(.0)	0(.0)	0(.0)	4(1.1)
71 – 80	0(.0)	0(.0)	0(.0)	8(2.2)
81+	0(.0)	0(.0)	0(.0)	4(1.1)
TOTAL	4(1.0)	24(6.4)	16(4.3)	336(88.3)

The Platelet counts were considered as abnormal ( $\leq 150 \times 10^9$ /L) and normal ( $\geq 150 \times 10^9$ /L – 450 x  $10^9$ /L)

302 303 304

301

305 In our locality where we do not have problem of distinguishing dengue from malaria that produces low 306 platelet counts<sup>22</sup>, hence platelet counts have been one of the most important factors in tracking the 307 progress of dengue infection. Monitoring platelet levels however, should not be the sole criteria to 308 presume dengue infection as many patients in this study tested dengue positive without abnormal platelet counts that is indicative of plasma leakage. In a study by Lovera et al, they investigated 309 310 platelet count as a risk factor of shock. Using a cut-off of  $< 100 \times 10^9$ /L they found that children who 311 did not develop shock exhibited similar percentage level of thrombocytopenia compared to patients who eventually developed it (47 % vs 49 %). The results were similar when the comparison included 312 313 patients only with platelet counts < 50,000/mL (28 % vs 25.6 %).<sup>23</sup> In this present study, the mean 314 platelet count for positive samples in patients 1- 10 years of age was 295 x 10<sup>9</sup>/L. Those with 315 abnormal counts were only found in the 21 – 30 year-old age group and 80% of them tested positive 316 for dengue virus. This adds up to 4.3% of those who tested positive but was not of any significance. 317 None of the patients had platelet levels that were  $< 50 \times 10^{9}$ /L. Lam et al reported and the WHO guideline states that, daily platelet counts can be used to predict the development of DSS.<sup>24, 25</sup>. Also in 318 319 an extensive review, Leal de Azeredo et al concluded that thrombocytopenia, coagulopathy, and 320 vasculopathy are hematological abnormalities related to platelet and endothelial dysfunction generally 321 observed in severe dengue.<sup>26</sup> We do not have proven explanations why majority of the patients who 322 were suspected of dengue in our study had normal plate counts, but we can only speculate that their 323 platelets were normal because they may have recovered. 324

325 The Pan American Health Organization (PAHO) has already issued a release of the number of 326 reported cases of dengue and severe dengue in the Americas by country for epidemiological week 39 (updated October 13, 2017). After week 32 in Trinidad and Tobago the number of probable reported cases were 206, none of which were laboratory confirmed<sup>10</sup>. This is as a result of non-availability of 327 328 329 the laboratory facilities because of lack of economic resources. It is however very critical that 330 identification, isolation of the virus or confirmation of the dengue diagnosis be made so that dengue 331 <mark>can successfully be managed and differentiated from other viral infections. It is also of</mark> utmost 332 importance that all probable cases not only be reported but confirmed, especially if headway is to be 333 made on curbing infection and development/implementation of a vaccine. The first dengue vaccine -334 the Sanofi CYD-TDV vaccine, has now been licensed by several endemic countries for use in 9-45 335 years and 9-60 year olds. The vaccine was unusual in that the recommended target population for 336 vaccination was not only defined by age but also by transmission setting as defined by 337 seroprevalence. The WHO has stated their position on the newly developed vaccine (CYD-TDV) 338 saying that countries should consider introduction of the dengue vaccine only in geographic settings where epidemiological data indicate a high burden of disease.<sup>27, 28</sup> The vaccine, also known as 339 340 Dengvaxia, is a live attenuated (recombinant) tetravalent vaccine that was created to be administered 341 by 3 doses of 0.5ml given at 6-month intervals. We cannot indicate high burden of disease if the 342 epidemiological data being collected is recorded incorrectly or disregarded. Hence, all assumptions 343 for diagnoses need to be confirmed by the most accurate methods. 344

#### 345 4. CONCLUSION

347 Despite the limitations of this study that include the small sample size and lack of use of molecular 348 tests, viral isolation or virus detection using indirect immunofluorescence for confirmation of dengue 349 virus, the study still detected positive cases of dengue virus infections in the country. Except for 350 nonspecific symptoms observed among patients suspected of dengue fever, there were no other 351 significant factors that were exclusive in identifying dengue infection among the subjects studied. 352 Platelet monitoring may not be the only parameter to use in determining deteriorating dengue 353 patients. Vector eradication activities in the country may not have been fully effective after all and so 354 attention may also focus on other areas such as education program.

#### CONSENT

356 357 358

359

360

355

Informed consent was also obtained from each of the patients, along with assent from children that were included in the study. Patients under the age of 18 were considered as children.

#### ETHICAL APPROVAL

361 362

363 Ethics approval for this study was obtained from the Campus Ethics Committee of the University of 364 the West Indies St. Augustine Campus and the North Central Regional Health Authority (NCRHA) 365 Ethics Committees. The study was carried out in accordance with the ethical standards laid down in 366 the 1964 declaration of Helsinki. 367

#### 368 REFERENCES

369 370 1. Velayudhan R. A WHO report on global strategy for dengue prevention and control 2012 – 2020; 371 WHO/HTM/NTD/VEM/2012.5. Accessed online from http://www.who.int/en/; July 31, 2018 372 2. Wesolowski A, Qureshi T, Boni MF, Sundsøy PR, Johansson MA, Rasheed BS, et al. Impact of human mobility on dengue epidemics. Proceedings of the National Academy of Sciences 2015; 112 373 374 (38) 11887-11892; DOI: 10.1073/pnas.1504964112 375 3. Tuyet-Hanh TT, Cam NN, Thanh Huong LT, Khanh Long T, Mai Kien T, Kim Hanh DT, Huu Quyen 376 N, et al. Climate variability and dengue hemorrhagic fever in Hanoi, Vietnam, during 2008 to 2015. 377 Asia pacific journal of public health, 2018: https://doi.org/10.1177/1010539518790143 378 4. Guzman A, Isturiz RE. Update on the global spread of Dengue. Int J Antimicrobial Agents 2010; 379 Suppl 1:S40-S42. 380 5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution 381 and burden of dengue. Nature 2013; 496:504-7 382 6. Gubler DJ. Dengue and dengue hemorrhagic fever. Lin Microbiol Rev 1998; 11:480-496. 7. Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): A 383 384 new public health dilemma in dengue control. Med J Armed Forces India 2015; 71(1), 67-70. 385 doi:10.1016/j.mjafi.2014.09.011 386 8. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S et al. Dengue 387 viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect 388 Dis 2000; 181(1), 2-9. doi:10.1086/315215 389 9. Thomas SJ, Endy TP, Rothman AL, Barrett AD. Flaviviruses (Dengue, Yellow Fever, Japanese 390 Encephalitis, West Nile Encephalitis, St. Louis Encephalitis, Tick-Borne Encephalitis, Kyasanur Forest 391 Disease, Alkhurma Hemorrhagic Fever, Zika). In Mandell, Douglas, and Bennett's Principles and 392 Practice of Infectious Diseases, 8<sup>th</sup> edition. Edited by: Bennett JE, Dolin R, Blasser MJ. Philadelphia, 393 PA 19103 -2899: Elsevier Saunders; 2015: Chapter 155, p1881 – 1906 394 10. PAHO. Number of Reported Cases of Dengue and Severe Dengue (SD) in the Americas, by 395 Country. Figures for 2016 (to week noted by each country). Epidemiological Week / EW 52 (Updated 396 February 6, 2017). Accessed online June 10, 2018 from www.paho.org/hg/dmdocuments/2016/2016-397 cha-dengue-cases-jan-26-ew-52.pdf

- 398 11. Chadee DD, Shivnauth B, Rawlins SC, Chen AA. Climate, mosquito indices and the epidemiology
- 399 of dengue fever in Trinidad (2002–2004). Annals of Tropical Medicine & Parasitology 2007; 101(1),
- 400 69-77. doi:10.1179/136485907X157059

- 401 12. Campbell CA, George A, Salas RA, Williams SA, Doon R, Chadee DD. Seroprevalence of dengue 402 in Trinidad using rapid test kits: a cord blood survey. Acta Trop 2007; 101(2), 153-158. 403 doi:10.1016/i.actatropica.2006.11.009 404 13. Chadee DD, Williams FL, Kitron UD. Impact of vector control on a dengue fever outbreak in 405 Trinidad, West Indies, in 1998. Trop Med Int Health 2005; 10(8), 748-754. doi:10.1111/j.1365-406 3156.2005.01449. 407 14. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition 2009; 408 World Health Organization. Accessed online June 10, 2018 from 409 www.who.int/rpc/guidelines/9789241547871/en 410 15. Parkash O, Shueb RH. Diagnosis of Dengue Infection Using Conventional and Biosensor Based 411 Techniques. Viruses 2015; 7(10), 5410-5427. doi:10.3390/v7102877 412 16. Anker M and Arima Y. Male-female differences in the number of reported incident dengue fever 413 cases in six Asian countries. Western Pacific Surveillance and Response Journal. 2011, 2(2):17-23. 414 doi:10.5365/wpsar.2011.2.1.002 415 17, Rojas PJH, Alzate A, Martínez Romero HJ, Concha-Eastman AI, Afro-Colombian ethnicity, a 416 paradoxical protective factor against Dengue. Colomb Med (Cali). 2016; 47(3):133-41. 417 18. Kyle JL, Harris E. Global spread and persistence of dengue. Anual Rev Microbiol 2008; 62:71-92. 418 19. Gregory J, Santiago LM, Arguello DF, Hunsperger E, Tomashek KM. Clinical and laboratory 419 features that differentiate dengue from other febrile illness in an endemic area - Peurto Rico, 2007 -420 2008. Am J Trop Med Hyg 2010; 82:922-929 421 20. WHO. Non communicable Diseases (NCD) Country Profiles, 2014: Trinidad and Tobago. 422 Accessed online June 10, 2018 from www.who.int/nmh/publications/ncd-profiles-2014/en 423 21. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, Lye DC. Diabetes with hypertension as 424 risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic; a 425 case control study. PloS Negl Trop Dis 2012; 6(5), e1641. doi:10.1371/journal.pntd.0001641 426 22. Chadwick D, Arch B, Wilder-Smith A, Panton N. Distinguishing dengue fever from other infections 427 on the basis of simple clinical and laboratory features: application of logistic regression analysis. J 428 Clin Virology 2006; 35:147-153 429 23. Lovera D, Martinez de Cuellar C, Araya S, Amarilla S, Gonzalez N, Aquiar C, Arbo A. Clinical 430 Characteristics and Risk Factors of Dengue Shock Syndrome in Children. Pediatr Infect Dis J 2016; 431 35(12), 1294-1299. doi:10.1097/INF.000000000001308 432 24. Lam PK, Ngoc TV, Thu Thuy TT, Hong Van NT, Nhu Thuy TT, Hoai Tam DT, et al. The value of 433 daily platelet counts for predicting dengue shock syndrome: Results from a prospective observational 434 study of 2301 Vietnamese children with dengue. PLoS Negl Trop Dis 2017; 11(4): e0005498. 435 https://doi.org/10.1371/journal.pntd.0005498 436 25. WHO, Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control, World Health 437 Organization, Geneva, Switzerland; 1997. Accessed online June 10, 2018 from: 438 http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/. 439 26. Leal de Azeredo E, Monteiro RQ, Pinto LM-O. Thrombocytopenia in Dengue: Interrelationship 440 between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. 441 Mediators of Inflammation, vol. 2015, Article ID 313842, 16 pages, 2015. https://doi.org/10.1155/2015/313842. 442 443 27. WHO. Dengue vaccine: WHO position paper Weekly Epidemiological Report 2016; 30(91), 349-444 364. 445 28. Imai N, Ferguson NM. Targeting vaccinations for the licensed dengue vaccine: Considerations for
- 446 serosurvey design. PLoS ONE 2018; 13(6): e0199450. https://doi.org/10.1371/journal. pone.0199450